Rafael Paletta da Silva

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study

Filipi Fim Andreão, Rafael Paletta da Silva, Maria Fernanda Liphaus Almeida Negreli, Ana Beatriz P. Aguiar-Barros et autres

Donanemab and Lecanemab are anti-amyloid monoclonal antibodies recently approved for the treatment of Alzheimer’s disease. Although their efficacy and safety have been investigated in randomized trials, real-world epidemiological data on treated populations remain limited. This study aimed to compare baseline clinical and …

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study

Filipi Fim Andreão, Rafael Paletta da Silva, Maria Fernanda Liphaus Almeida Negreli, Ana Beatriz P. Aguiar-Barros et autres

Donanemab and Lecanemab are anti-amyloid monoclonal antibodies recently approved for the treatment of Alzheimer’s disease. Although their efficacy and safety have been investigated in randomized trials, real-world epidemiological data on treated populations remain limited. This study aimed to compare baseline clinical and …

Cognitive assessment in Neuromyelitis Optica spectrum disorders: A systematic review and meta-analysis

Filipi Fim Andreão, Lucas Macedo Nascimento, Helvécio Neves Feitosa Filho, Rafael Paletta da Silva et autres

br (code pays fourni par la source)

Efficacy and safety of intravenous tirofiban in patients with acute ischemic stroke due to large artery atherosclerosis undergoing endovascular thrombectomy: A systematic review and meta-analysis

Ocílio Ribeiro Gonçalves, Frederico de Sousa Marinho Mendes Filho, Filipe Virgílio Ribeiro, Saul Dominici et autres

br (code pays fourni par la source)

Effectiveness and Safety of Edoxaban in the Routine Clinical Care of Atrial Fibrillation Patients in Brazil: Prospective 1-Year Follow-Up Study – EdoBRA

Dalton Bertolim Précoma, Rafael Paletta da Silva, Luíz Carlos Santana Passos, Fábio Serra Silveira et autres

Abstract Background Edoxaban, an orally administered anticoagulant, has been shown to be safe and effective in preventing stroke in atrial fibrillation (AF) patients. Given its widespread use since approval, evaluating edoxaban’s real-world performance in the Brazilian clinical context is crucial. Objective The …

de, br, gb (code pays fourni par la source)

Efetividade e Segurança da Edoxabana nos Cuidados Clínicos de Rotina de Pacientes com Fibrilação Atrial no Brasil: Estudo Prospectivo de Acompanhamento de 1 Ano – EdoBRA

Dalton Bertolim Précoma, Rafael Paletta da Silva, Luiz Carlos Santana Passos, Fábio Serra Silveira et autres

BACKGROUND: Edoxaban, an orally administered anticoagulant, has been shown to be safe and effective in preventing stroke in atrial fibrillation (AF) patients. Given its widespread use since approval, evaluating edoxaban's real-world performance in the Brazilian clinical context is crucial. OBJECTIVE: The study …

de, br, gb (code pays fourni par la source)

IMPACTOS TECNOLÓGICOS NA VIDA CONTEMPORÂNEA: A HIPERVULNERABILIDADE DOS IDOSOS NO CIBERESPAÇO

Bruna Ewerling, Ana Paula Koenig, Rafael Paletta da Silva

O presente trabalho tem como objetivo analisar os impactos tecnológicos na vida contemporânea, com foco específico na hipervulnerabilidade dos idosos no ciberespaço. A temática se justifica em razão da influência das transformações tecnológicas na sociedade contemporânea, sendo inseridas nas relações de consumo …

br (code pays fourni par la source)

Desenho de Estudo de um Estudo Observacional Brasileiro sobre o uso de Edoxabana em Pacientes com Fibrilação Atrial (EdoBRA)

Dalton Bertolim Précoma, Rafael Paletta da Silva, Allyson Nakamoto, Viviane Mariz Omar et autres

BACKGROUND: Clinical trials showed the safety of Edoxaban, a non-vitamin K-dependent oral anticoagulant (NOAC), and its efficacy to prevent stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients and also to prevent and treat venous thromboembolism. However, additional research is needed …

us, de, br (code pays fourni par la source)

Study Design of a Brazilian Observational Study of Edoxaban in Patients with Atrial Fibrillation (EdoBRA)

Dalton Bertolim Précoma, Rafael Paletta da Silva, Allyson Nakamoto, Viviane Mariz Omar et autres

Abstract Background: Clinical trials showed the safety of Edoxaban, a non-vitamin K-dependent oral anticoagulant (NOAC), and its efficacy to prevent stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients and also to prevent and treat venous thromboembolism. However, additional research is …

us, de, br (code pays fourni par la source)

Cognitive training associated with transcranial direct current stimulation in the treatment of age-related mild cognitive impairment: a systematic review of randomized clinical trials

Felipe Miranda Camboim, Daniela Oliveira, João Vítor Andrade Fernandes, Rafael Paletta da Silva et autres

Background: Cognitive training (CT) is an established therapy for cognitive decline in ,ild cognitive impairment (MCI), however, there are other non-pharmacological alternatives, such as transcranial direct current stimulation (tDCS). A novel approach suggests combining both CT and tDCS, in an attempt to …

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel et autres

BACKGROUND: Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. METHODS AND RESULTS: In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for …

us, de, au, gb (code pays fourni par la source)